expected to reach USD 60.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected
to expand at a CAGR of 6.4% from 2021 to 2028. An increase in the prevalence of eye-related disorders, such as presbyopia, macular degeneration, and diabetic retinopathy, is one of the major drivers of the market. According to the American Academy of Ophthalmology, over 2.71 million people in the U.S. were affected by Primary Open-angle Glaucoma (POAG) in 2011, and the number is estimated to reach 7.3 million by 2050.
Key suggestions from the report:
In 2020, anti-VEGF agents dominated the market owing to high preference by ophthalmologists, enhanced tissue penetration, and rapid responsive rates